trx518
mAbexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2010 (NCT01239134)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
TNFRSF18 agonist
TNFRSF18 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109428 ↗
Also known as
- trx518
- trx-518
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03861403 | Phase 1/Phase 2 (Phase 2) | May 15, 2019 | Leap Therapeutics, Inc., Merck KGaA, Pfizer |
| NCT02628574 | Phase 1 | Dec 1, 2015 | Leap Therapeutics, Inc. |
| NCT01239134 | Phase 1 | Oct 1, 2010 | Cancer Research Institute, Cornell University, Leap Therapeutics, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Leap Therapeutics, Inc. | For profit | 3 | 3 | 2 | 2010 |
| Cancer Research Institute | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Cornell University | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Merck KGaA | For profit | 1 | 0 | 1 | 2019 |
| Pfizer | For profit | 1 | 0 | 1 | 2019 |
5 organizations
Page 1 / 1